Authors
Latest:
Remembering That TIME Magazine Issue; Celebrating Progress in Patient EngagementLooking to the past reminds industry of great strides taken in clinical research for patients.
Latest:
The View From the ForefrontMatthew Howes, President at Greater Than One, discusses what to expect in the next twelve months in healthcare marketing.
Latest:
Empowering Prior Authorization ProfessionalsA look at the rise of prior authorization certified specialists (PACS)—and their value in improving patient access and outcomes.
Latest:
Don’t Waste A Crisis: How Paratek is Navigating the Business Implications of the COVID-19 PandemicA look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.
Latest:
‘Selling a Vision’: Today’s Playbook for StartupsThe Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
Latest:
Beyond Medicines: Pharma's Journey with Patient Family Advisory CouncilsIncluding patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.
Latest:
New Technologies Come with New Litigation RisksCybersecurity vulnerabilities embedded in AI and machine learning pose significant litigation risks as life sciences companies move to digital technologies.
Latest:
The Untapped Potential of Behavioral Science in Medical AffairsHistorically, Medical Affairs teams have relied on reporting only empirical evidence such as efficacy and tolerability profiles to influence uptake of a new drug or therapy. Here, Ben Routley and Mark Pringle explore the scope for applying behavioral science techniques to improve the impact of client communications.
Latest:
As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally AdaptU.S. patent law will have to adapt to the use of AI in the life sciences industry.
Latest:
Uncovering the Missing Link in AI-Enhanced Field Rep SupportWebinar Date/Time: Thu, Oct 17, 2024 11:00 AM EDT
Latest:
Comparing Three Common Pharma Communication AvenuesPavel Klymenko, Head of Omnichannel at Viseven, compares three top approaches to pharma communication and elucidates which are here to stay.
Latest:
How Biopharma Can Accelerate Innovation and Sustain GrowthThere are clear pathways that biopharma companies can take to sustain growth and remain competitive.
Latest:
How to Stand Out in the Wellness Space as a Pharma BrandKey steps in relationship-building beyond just treatment options.
Latest:
Defending Against Label-Based LawsuitsBest practices for defending against lawsuits based on pharmaceutical labeling, including avenues for early resolution of the case and, as necessary, strategies for developing the best evidence for defense.
Latest:
How COVID-19 Has Affected Launches of New Oncology Therapies in the U.S.Several months into the COVID-19 pandemic, this article takes a look back at how the launches of new oncology therapies have been impacted.
Latest:
IDN Trends, Insights and Strategies Every Manufacturer Should KnowWebinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT
Latest:
How and Why the New ‘Over-Time’ Is Transforming the Work of Medical AffairsWhat’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.
Latest:
The Tech Perspective: Coordinating a Plan of EngagementDesigning an omnichannel artificial intelligence ecosystem that integrates strategies can boost commercial success for pharma.
Latest:
3 Steps to Supercharge Your Rare Disease Advocacy PartnershipsHow these actions can help brand teams form effective and sustainable relationships with patient communities
Latest:
Evolving a Market Access Strategy to Improve Patient AccessDavid Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments.
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
Market Access Speed Is the Next Critical Differentiator for Pharma ManufacturersNew technology forces industry to increase urgency.
Latest:
Food for Thought: Make Room for Multiple OpinionsThe rise of DOLs doesn’t mean pharma should upend KOL approach.
Latest:
Drug Launch: Winning the Evidence BattleBeyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
Latest:
A Better Way to Combat Patent TrollsCross-sector businesses are banding together to protect their intellectual property, but there’s a better way to do it.
Latest:
Partnering to Respond to a Possible Nuclear ThreatRecent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.
Latest:
Outsourcing’s Evolution in the Pharma IndustryAmid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.
Latest:
Applying the Scientific Method as the Cornerstone of Brand StrategyHow commercial teams can benefit from a more scientifically rigorous approach to insights generation
Latest:
FDA Inspection and Enforcement Developments During the COVID-19 PandemicMitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
